Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(148)

カスタマーフィードバック(25)

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MWXDfZRwfG:6aXOgRZN{[Xl? M{LX[FUxKM7:TR?= NIjwTVM1QCCq M3vaZ2ROW09? NXW5RnNDU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? M4DVVlExPDl7NkSz
OVCA 429 NH[2TXhHfW6ldHnvckBCe3OjeR?= NFTXVHY{ODBibl2= MUm0PEBp M3PwfGROW09? NU\OcFJqTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ NWO2R4Q3OTB7OUm3OlY>
RPMI8226 M2fneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO4NVAxKG6P M1K5RlQ5KGh? MVfEUXNQ MVLJR|UxRTNyIH7N MnTINVE{ODZ2OEm=
Dox40 NUHHRYJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T4R|ExOCCwTR?= MofkOFghcA>? MnLUSG1UVw>? NVnYfZBPUUN3ME20NEBvVQ>? NITYSYkyOTNyNkS4PS=>
MR20 NEPnT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTkNVAxKG6P MYq0PEBp M3PEdWROW09? NFTSVmZKSzVyPUKwJI5O NVS0Z4pxOTF|ME[0PFk>
LR5 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWxNFAhdk1? M1z6NlQ5KGh? NV7SO3d7TE2VTx?= MVLJR|UxRTJyIH7N MnrTNVE{ODZ2OEm=
U266 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P5ZlExOCCwTR?= MlHpOFghcA>? MX3EUXNQ NF6zbVJKSzVyPUOgcm0> NH64TngyOTNyNkS4PS=>
IM-9 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzYNVAxKG6P MY[0PEBp NEnRb4tFVVOR NGfHbFZKSzVyPU[gcm0> NYD6TY9nOTF|ME[0PFk>
Hs Sultan MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jzVFExOCCwTR?= M1nIN|Q5KGh? NFP3SY1FVVOR MWfJR|UxRTJyIH7N NUfibGZxOTF|ME[0PFk>
PAM-LY2 NFnrepFHfW6ldHnvckBCe3OjeR?= MkjrNVAxKG6P NFT3XZQyOiCq NUHVTFFrTE2VTx?= M1jnRWlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u MX[xNVM2ODlzMx?=
PAM 212 NVfqeo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfDcWZZOTByIH7N Mm\SO|IhcA>? MmfUSG1UVw>? NIewRm1KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mkj4NVE{PTB7MUO=
PAM-LY2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvcFExOCCwTR?= NYXEeYtvPzJiaB?= NUTnZlh5TE2VTx?= M4n5S2lvcGmkaYTzJINmdGxidnnhZoltcXS7 Ml[3NVE{PTB7MUO=
B4B8 NE\VOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW3UYgyODBibl2= M{nSOFczKGh? MYXEUXNQ MYjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NHfNR5EyOTN3MEmxNy=>
B7E3 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnLNVAxKG6P MmTDO|IhcA>? M3fBUWROW09? MULJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M2C1eVEyOzVyOUGz
UM-SCC-9 NY\Sd|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJNVAxKG6P MUK3NkBp M2\LNWROW09? NUD0VGVSUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MmLKNVE{PTB7MUO=
UM-SCC-11B MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf3d4YyODBibl2= MoX1O|IhcA>? NWLUSZdzTE2VTx?= MULJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NYrqeVR2OTF|NUC5NVM>
H460 M3Sx[mZ2dmO2aX;uJGF{e2G7 NVX5c4xLOTBizszN M3Kz[|I1KGh? M3G2b2ROW09? MV\JcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 NVvWeXVzOTJ2OUKxNVc>
U266 M3f4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPrOVAxKG6pL33s NH33flk1QCCq NFe3VGFFVVOR MWnJcohq[mm2czDj[YxtKGe{b4f0bC=> M3W0cFEzPjNzNkG5
ARH77 M1f0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjPHI2ODBibnevcYw> M4LhW|Q5KGh? MlzQSG1UVw>? Mn3hTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NY\iUotLOTJ4M{G2NVk>
WAD-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[0cZhyPTByIH7nM41t NFfJNlU1QCCq NWXuV2RGTE2VTx?= MkXrTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHjJdXIyOjZ|MU[xPS=>
U266/LR7 NYXLeHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nD[lUxOCCwZz;tcC=> NH\qOIs1QCCq M2TzRmROW09? M{XJZmlvcGmkaYTzJINmdGxiZ4Lve5Rp NFfaO4wyOjZ|MU[xPS=>
U266/dox4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\0XGw2ODBibnevcYw> Mn\sOFghcA>? M2DpOWROW09? NF\BcopKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHT0NZMyOjZ|MU[xPS=>
RPMI8226/LR5 NFTReG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzvcok2ODBibnevcYw> MknCOFghcA>? Moq1SG1UVw>? NHvVdZBKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIrKV5IyOjZ|MU[xPS=>
H460 M4fNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrifGJiOTBizszN MofoO|IhcA>? NVzmRmRDTE2VTx?= Ml6xTWM2OD1zMECgcm0> M2DTcFEzPjNzNkKw
H358 NGryO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfKVVY5OTBizszN NYT3V4VkPzJiaB?= MXjEUXNQ NHu3O2VKSzVyPUewJI5O NWXBSWhPOTJ4M{G2NlA>
H322 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjkRVNKOTBizszN M1PjTFczKGh? M{LMTmROW09? MWXJR|UxRTZ{MDDuUS=> M{n6d|EzPjNzNkKw
H460 M3fUOGZ2dmO2aX;uJGF{e2G7 NFvmbJoyODBibl2= M{nUb|I1KGh? Ml7OSG1UVw>? MnzXTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NHe3R5QyOjZ|MU[yNC=>
LNCap-Pro5 NGLZO5JHfW6ldHnvckBCe3OjeR?= MnezNUDPxE1? NHLWSpk1KGh? NYW4dJluTE2VTx?= NYmxdWJ4W3SjYnnsbZpmeyCyNUO= Mm\pNVQ3OTJ3M{K=
T29 NYP6WXVKSXCxcITvd4l{KEG|c3H5 MXm1NEBvVQ>? Mn;5OFghcCB? MkjnSG1UVw>? MYjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NF;T[5gyPjd5OEG3PS=>
T29Kt1 MU\BdI9xfG:|aYOgRZN{[Xl? MkDTOVAhdk1? MUm0PEBpKA>? NEG2XZZFVVOR M4ToZWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnX3NVY4PzhzN{m=
HCT116 MVTBdI9xfG:|aYOgRZN{[Xl? MWK1NEBvVQ>? MYO0PEBpKA>? NH;nSllFVVOR NVW5O2lHUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmnVNVY4PzhzN{m=
HKe-3 NEnIZlVCeG:ydH;zbZMhSXO|YYm= NIHpbGM2OCCwTR?= M{[1c|Q5KGhi MkjZSG1UVw>? MnnmTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MX:xOlc4QDF5OR?=
NB-1691 NXX2SIh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HXO|Eh|ryP M2\xRlczKGh? M4XST2lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NGnjTmMyPzZ6OU[4OC=>
CHLA-255 M{\OXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxJO69VQ>? NGPQSXA4OiCq NEjwV45KdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW= NGPHb|gyPzZ6OU[4OC=>
SK-N-AS MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj2NUDPxE1? MYm3NkBp MnLnTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= M3vUdFE4Pjh7Nki0
NB-1691 M1iyT2Z2dmO2aX;uJGF{e2G7 MlHCNVAhdk1? NXP5V3N5OjRiaB?= NH\DeWtUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm M2HMS|E4Pjh7Nki0
CHLA-255 NGOzcpNHfW6ldHnvckBCe3OjeR?= MWexNEBvVQ>? M2npdVI1KGh? NUfnV2gyVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= MWexO|Y5QTZ6NB?=
RPMI 8226 NYnNXFlMTnWwY4Tpc44hSXO|YYm= M2D3R|IxKG6P NGDMXWg5KGh? MVPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MnL6NVk1OzZyNUC=
MM.1S M{HVNWZ2dmO2aX;uJGF{e2G7 NXPzUXV[OjBibl2= M3z6NFghcA>? NInybW9UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M4G5Z|E6PDN4MEWw
U266 M32wNWZ2dmO2aX;uJGF{e2G7 NFv3b|IzOCCwTR?= MYS4JIg> MYrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NXHU[nluOTl2M{[wOVA>
OPM1 MoXxSpVv[3Srb36gRZN{[Xl? NIfRcXEzOCCwTR?= NUi2SWVNQCCq M4CybHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MlHkNVk1OzZyNUC=
INA6 NI\nUJJHfW6ldHnvckBCe3OjeR?= NHvGenUzOCCwTR?= M{jBVFghcA>? MXjTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NG\KcJMyQTR|NkC1NC=>
OPM2 MVvGeY5kfGmxbjDBd5NigQ>? MX2yNEBvVQ>? Mon3PEBp NHn4cIZUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? Mm\oNVk1OzZyNUC=
RPMI 8226 MX7GeY5kfGmxbjDBd5NigQ>? NUWxeoo1OjBibl2= Mn\FPEBp MYrJcoR2[2W|IFTORUB{gW62aHXzbZM> M1PvZVE6PDN4MEWw
BaF/3 NGXnTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;TR5o{OTByIH7N MYS0PEBp Ml;wTWM2OD14LkKgcm0> M3uzVFIxOzB3Nkmy
BaF/3-p210 NYPSVWhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixNFAhdk1? NYTEO|RXPDhiaB?= MlzDTWM2OD12Lkegcm0> MXyyNFMxPTZ7Mh?=
TCC-S NWXI[HRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\QVldzOTByIH7N MVy0PEBp MoHHTWM2OD1{Lkigcm0> NE[4VHAzODNyNU[5Ni=>
BaF/3 M1OxSGZ2dmO2aX;uJGF{e2G7 Ml7QOkBvVQ>? NVrQXlJCPDhiaB?= NH\HbZNKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> MYiyNFMxPTZ7Mh?=
BaF/3-p210 M{jyOmZ2dmO2aX;uJGF{e2G7 NHn3[Wo3KG6P NVfsUHZvPDhiaB?= NETDfoxKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MV2yNFMxPTZ7Mh?=
BaF/3-p210 NIjMRYZHfW6ldHnvckBCe3OjeR?= NVrzepBkPiCwTR?= M136VlI1KGh? NE\xbFZT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= MUeyNFMxPTZ7Mh?=
Raji MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrS[mhvOSEQvF2= MV2yOEBp MW\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MkDaNlEyPzB7OEi=
LCL-1 M3\UXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO4NUDPxE1? NH33W|QzPCCq MkjmVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MorLNlEyPzB7OEi=
LCL-2 NWrJZlBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;mOmlEOSEQvF2= M4K3VVI1KGh? NFzTS4NT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MYKyNVE4ODl6OB?=
BJAB NGPBN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxJO69VQ>? NV7VTXNEOjRiaB?= MUTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{\2TVIyOTdyOUi4
SNT-13 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDtNUDPxE1? M2DMS|I1KGh? NV20dHFqWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NYm2PVFWOjFzN{C5PFg>
SNT-16 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxJO69VQ>? MX6yOEBp MYXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MXKyNVE4ODl6OB?=
Jurkat NIPDO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPQNUDPxE1? M{XwS|I1KGh? MV;S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NWXQVVVDOjFzN{C5PFg>
KAI-3 M4\jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxJO69VQ>? M2rkNFI1KGh? NXTRSm5tWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NXPHfGtiOjFzN{C5PFg>
SNK-6 NFnzNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfSRWRqOSEQvF2= MnXWNlQhcA>? NHHYN|hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MoD0NlEyPzB7OEi=
KHYG-1 M1Pr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrWbZBPOSEQvF2= M1mwSlI1KGh? NV;afZVMWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MUiyNVE4ODl6OB?=
SNT-16 MWjBdI9xfG:|aYOgRZN{[Xl? NYDPZlVuOSEQvF2= MXK2JIg> NHzJfpNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3XRfVIyOTdyOUi4
Jurkat NEPrVodCeG:ydH;zbZMhSXO|YYm= NYnQXYtFOSEQvF2= M1Lnc|YhcA>? MVjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVWyNVE4ODl6OB?=
KAI-3 M{\leWFxd3C2b4Ppd{BCe3OjeR?= MXmxJO69VQ>? NW\Ud|JsPiCq NWftXFFMUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlvaNlEyPzB7OEi=
KHYG-1 MnrXRZBweHSxc3nzJGF{e2G7 MVOxJO69VQ>? M37OZlYhcA>? Ml6yTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFLaUHIzOTF5MEm4PC=>
SNT-13 MUXBcpRqfmm{YXygRZN{[Xl? Ml7FNUDPxE1? MXOyOEBp MlTOTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX M1;0[|IyOTdyOUi4
SNT-16 Mm\YRY51cX[rcnHsJGF{e2G7 NFT0TVYyKM7:TR?= M{HwU|I1KGh? MnzjTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NX\nZnBKOjFzN{C5PFg>
KAI-3 NFrHXo5CdnSrdnnyZYwhSXO|YYm= NIrYbWYyKM7:TR?= NYLQTJhJOjRiaB?= NHzjN3BKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NH;jTYczOTF5MEm4PC=>
SNK-6 NV7GSYFYSW62aY\pdoFtKEG|c3H5 M3jrNFEh|ryP NX\Z[ldIOjRiaB?= NGPrephKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NHzSS5kzOTF5MEm4PC=>
RAW 264.7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[2NVAxKG6P M1S4VlQ5KGh? MY\S[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NX71OIpROjJ2MkexOVQ>
A375 MX\BdI9xfG:|aYOgRZN{[Xl? Mom4NVAhdk1? NH;XbI4zPCCq NX;TfGhzUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mnj2NlMxPzlyOEO=
BLM NYjpUHd7SXCxcITvd4l{KEG|c3H5 MX[xNEBvVQ>? NIXMZ3gzPCCq NIjseWVKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M36yfVI{ODd7MEiz
A375 M2Do[2F2fG:yaHHnfUBCe3OjeR?= M{PKWVExKG6P M1\GbVEzKGh? MVzJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NEOxSZYzOzB5OUC4Ny=>
BLM NETnbpZCfXSxcHjh[5khSXO|YYm= NF2xOnQyOCCwTR?= MVmxNkBp M2D0c2lv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NFXw[YczOzB5OUC4Ny=>
H1299 NEDBfZBCeG:ydH;zbZMhSXO|YYm= MYC4NEBvVQ>? NXz3NWNoOjRiaB?= MlPvSG1UVw>? MkPtV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? M3jYO|I2OzJ|Nkmz
Hut-78 NWXl[YZqTnWwY4Tpc44hSXO|YYm= NX7Y[ZZpOTByIH7N NIfmXJMzPCCq M1OwUWROW09? NV;0e|d3TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u MXuyOVY5OTN|NR?=
H9 NHfISZlHfW6ldHnvckBCe3OjeR?= MVmxNFAhdk1? M2\Kc|I1KGh? Ml6ySG1UVw>? Mn32SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w M2j3NlI2PjhzM{O1
HH NIPPO3NHfW6ldHnvckBCe3OjeR?= NXHBfZFnOTByIH7N NXPsRpM2OjRiaB?= MYDEUXNQ MYjkc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? NHTPeIgzPTZ6MUOzOS=>
Hut-78 MY\NbYdz[XSrb36gRZN{[Xl? NGG4RpYyODBibl2= M1exWlI1KGh? MWrEUXNQ NWLscpY1WmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> M1zWb|I2PjhzM{O1
HH NHzvOHZOcWe{YYTpc44hSXO|YYm= NX3keWI2OTByIH7N NX\0SWdkOjRiaB?= MoTUSG1UVw>? NUjaT4dmWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> NFLkXpAzPTZ6MUOzOS=>
U937 M3rtVmZ2dmO2aX;uJGF{e2G7 NGHlfFEyODBibl2= MmPKOkBp M4\qWGlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? MnfpNlU4QTF2N{e=
human PBMC M2exNGZ2dmO2aX;uJGF{e2G7 NFLOTmIyODBibl2= MnrBNlQhcA>? NIr1SnFKdmS3Y3XzJGlNNThicnXs[YF{\Q>? MUeyOVc6OTR5Nx?=
ES6 NFTmeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\2N3FoUUN3ME2wMlAxOjFibl2= MmfMV2FPT0WU
SK-UT-1 NFi0WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMXGlEPTB;MD6xOlMhdk1? MU\TRW5ITVJ?
SH-4 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUezJI5O NGDRcmxUSU6JRWK=
TE-9 NF74XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i2VmlEPTB;MD6xPFIhdk1? NGnHRZFUSU6JRWK=
A253 NInGRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG2VpVuUUN3ME2wMlIxQCCwTR?= MVrTRW5ITVJ?
no-10 M3Tyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr3TWM2OD1yLkKxJI5O MYfTRW5ITVJ?
MMAC-SF M1L3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\lWmJxUUN3ME2wMlIyPiCwTR?= NF;WVIFUSU6JRWK=
A101D NIf1NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33cJhKSzVyPUCuNlI2KG6P NGPKO3dUSU6JRWK=
NTERA-S-cl-D1 M1TGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLkTWM2OD1yLkK0N{BvVQ>? M2nDUXNCVkeHUh?=
8-MG-BA M4LFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHGTWM2OD1yLkK1JI5O M{PTUXNCVkeHUh?=
KNS-42 M1rofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHFTWM2OD1yLkK1PEBvVQ>? MlO2V2FPT0WU
LXF-289 NH\4[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3GTWM2OD1yLkK2PUBvVQ>? NEXneZFUSU6JRWK=
OVCAR-4 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfWTWM2OD1yLkK4PUBvVQ>? M4frNHNCVkeHUh?=
LOUCY NXO5RXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDnVXplUUN3ME2wMlI6OyCwTR?= Ml2zV2FPT0WU
BB65-RCC M4CyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwM{C0JI5O NIfP[pFUSU6JRWK=
D-542MG NX;MUVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD1yLkOyPUBvVQ>? M2G4VnNCVkeHUh?=
ONS-76 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{Ogcm0> MUjTRW5ITVJ?
BB30-HNC M{Hl[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nxNGlEPTB;MD6zN|Uhdk1? NHq3VoFUSU6JRWK=
KS-1 NX7tNG1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fndmlEPTB;MD6zOEBvVQ>? MUHTRW5ITVJ?
A388 NF;FN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvrU3h3UUN3ME2wMlM2PiCwTR?= Mof6V2FPT0WU
ES8 NU\RTHpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ETWM2OD1yLkSgcm0> M3HTV3NCVkeHUh?=
MZ2-MEL NUjaN3d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNEC3JI5O NXPJU|BWW0GQR1XS
HCC2998 NHnzPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7ySopqUUN3ME2wMlQyOiCwTR?= MVrTRW5ITVJ?
D-247MG MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj4OI1KSzVyPUCuOFE{KG6P MWTTRW5ITVJ?
ACN MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nFWmlEPTB;MD60NVchdk1? NYXEWI9oW0GQR1XS
LB2518-MEL MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNEK1JI5O NHXVcIFUSU6JRWK=
ES1 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNEOgcm0> NWrDSohPW0GQR1XS
HCE-T M{PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ZUWI3UUN3ME2wMlQ{QSCwTR?= MV;TRW5ITVJ?
OS-RC-2 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu0UnpHUUN3ME2wMlQ1KG6P MXrTRW5ITVJ?
MFH-ino M4P2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwNESzJI5O MkLpV2FPT0WU
OCUB-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;TTWM2OD1yLkS0O{BvVQ>? MmO4V2FPT0WU
CP66-MEL NEDNcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNEezJI5O Mn3MV2FPT0WU
LB771-HNC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3IboVKSzVyPUCuOFc1KG6P Mn\KV2FPT0WU
DSH1 M2LSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjzTWM2OD1yLkS4JI5O MkDnV2FPT0WU
HUTU-80 NX3RVno3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\wdFBUUUN3ME2wMlU{OyCwTR?= MoTZV2FPT0WU
CESS M2\t[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr1[YZXUUN3ME2wMlU{QCCwTR?= MX;TRW5ITVJ?
NCI-H747 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fab2lEPTB;MD61N|khdk1? NEDVc45USU6JRWK=
HT-144 NYTyOVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fqfWlEPTB;MD61O|Yhdk1? MY\TRW5ITVJ?
COLO-829 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO5TWM2OD1yLk[xOEBvVQ>? MV7TRW5ITVJ?
A4-Fuk MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fucmlEPTB;MD62NlMhdk1? NF74S2lUSU6JRWK=
GI-ME-N M1S4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WyUmlEPTB;MD62N|Qhdk1? MWrTRW5ITVJ?
LB831-BLC NXj0Z|cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ONWZIUUN3ME2wMlY1OSCwTR?= MUfTRW5ITVJ?
HOP-62 NYnuZYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwNkS3JI5O M2\DZ3NCVkeHUh?=
BB49-HNC M3LIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fsVGlEPTB;MD62OVIhdk1? M4Tv[XNCVkeHUh?=
D-336MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjheVR4UUN3ME2wMlY2PyCwTR?= M2XIbnNCVkeHUh?=
TK10 NVriN417T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyxdHdKSzVyPUCuOlc6KG6P MWDTRW5ITVJ?
Ramos-2G6-4C10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLETWM2OD1yLk[5N{BvVQ>? NIrFZpFUSU6JRWK=
LB373-MEL-D NHvQeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4S2lEPTB;MD63JI5O MkXRV2FPT0WU
SF126 NGrzZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXEU2dKSzVyPUCuO|AyKG6P NFy4N3dUSU6JRWK=
UACC-257 NXfqVppbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LsU2lEPTB;MD63NUBvVQ>? MmXVV2FPT0WU
KINGS-1 M2TVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonuTWM2OD1yLkeyNkBvVQ>? MmXMV2FPT0WU
LS-513 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnGUmFKSzVyPUCuO|M6KG6P NUf3NIF3W0GQR1XS
GI-1 NYL0O3FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwN{[0JI5O MX\TRW5ITVJ?
ES7 M4rnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTyfJpMUUN3ME2wMlc3PiCwTR?= MkXXV2FPT0WU
LB2241-RCC MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;ySlZKSzVyPUCuPFA1KG6P NFXZbIxUSU6JRWK=
D-263MG M1jSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwOEC3JI5O NYjPdHZ3W0GQR1XS
SW684 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwOEKxJI5O M4rUTHNCVkeHUh?=
ML-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwOEKxJI5O NH7K[IxUSU6JRWK=
SK-LMS-1 M{PkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwOEW0JI5O MUPTRW5ITVJ?
TE-5 M1TPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnDTWM2OD1yLki2OUBvVQ>? MULTRW5ITVJ?
QIMR-WIL M3G4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX6TWM2OD1yLki4PUBvVQ>? MVXTRW5ITVJ?
NCI-H1355 M4L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOzTWM2OD1yLki5OUBvVQ>? MU\TRW5ITVJ?
SNB75 NXS0cop3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm0RW9KSzVyPUCuPVEzKG6P M4KwPXNCVkeHUh?=
RXF393 M{[3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLQW|ZKSzVyPUCuPVE1KG6P M3f3eHNCVkeHUh?=
IST-MEL1 NG\zPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4OJkzUUN3ME2wMlkyPyCwTR?= NHjmZppUSU6JRWK=
SF268 NVztOGRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPlSZBKSzVyPUCuPVI{KG6P NV\tVmt6W0GQR1XS
KALS-1 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwOUK1JI5O MoXVV2FPT0WU
HC-1 NFPqSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSxclZKSzVyPUCuPVc2KG6P M160cHNCVkeHUh?=
SW872 M2mydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHzN3FKSzVyPUCuPVk3KG6P M1f6NnNCVkeHUh?=
PSN1 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDbJc6UUN3ME2xMlAyKG6P M3nSO3NCVkeHUh?=
TE-1 NYqwUFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXTV4JKSzVyPUGuNFMhdk1? NInL[ZdUSU6JRWK=
TE-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf4T4dKSzVyPUGuNFMhdk1? NF[yV|RUSU6JRWK=
RKO M3KxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PjSWlEPTB;MT6wOkBvVQ>? NI\uTYtUSU6JRWK=
LC-2-ad MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD0ZlduUUN3ME2xMlA5KG6P NWHuO2JRW0GQR1XS
SK-MM-2 M2PqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwMEmgcm0> MnflV2FPT0WU
VA-ES-BJ MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jUOmlEPTB;MT6wPUBvVQ>? M{X6[HNCVkeHUh?=
MZ7-mel NITWdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;pRnlKSzVyPUGuNFkhdk1? NYnvWY4yW0GQR1XS
D-392MG MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nWZ2lEPTB;MT6xJI5O M1rR[3NCVkeHUh?=
CCRF-CEM M4ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXm[mNKSzVyPUGuNVMhdk1? NV3TXWtSW0GQR1XS
EM-2 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjwTWM2OD1zLkG2JI5O NF7hcHVUSU6JRWK=
HAL-01 NELJSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHCTWM2OD1zLkG4JI5O NXe1WXBtW0GQR1XS
TE-8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm5WWJKSzVyPUGuNVkhdk1? NWPjfGk2W0GQR1XS
NCI-H1882 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvtTWM2OD1zLkKgcm0> MUnTRW5ITVJ?
Daudi MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dle2lEPTB;MT6yNkBvVQ>? M1;rVnNCVkeHUh?=
BL-41 NH20T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\BTWM2OD1zLkK1JI5O M2n5N3NCVkeHUh?=
SR M2XUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLCOXJ[UUN3ME2xMlI2KG6P MnzCV2FPT0WU
KM12 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TkZ2lEPTB;MT6yO{BvVQ>? MUfTRW5ITVJ?
K5 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;BbmlEPTB;MT6yPEBvVQ>? MlLEV2FPT0WU
A3-KAW M{[zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP0TWM2OD1zLkK4JI5O M3HyUHNCVkeHUh?=
CMK NVfkd5A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwMkmgcm0> NX7kOHJbW0GQR1XS
Calu-6 NWL4S5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm1TWM2OD1zLkK5JI5O M{G5S3NCVkeHUh?=
IST-SL2 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXwPY1HUUN3ME2xMlMyKG6P MYTTRW5ITVJ?
OPM-2 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKxT4hEUUN3ME2xMlM{KG6P MUTTRW5ITVJ?
DU-4475 NWftbpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorsTWM2OD1zLkO2JI5O MnXEV2FPT0WU
ECC12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwM{egcm0> MkPNV2FPT0WU
L-540 M3XCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHzd4RKSzVyPUGuN|chdk1? MVvTRW5ITVJ?
CAS-1 M2Hydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W0NWlEPTB;MT6zO{BvVQ>? MUjTRW5ITVJ?
PF-382 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwNEegcm0> M2KyRnNCVkeHUh?=
LS-411N M4HafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLVPJlKSzVyPUGuOVMhdk1? M1\6[nNCVkeHUh?=
NCI-H69 NXz6XWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwNUSgcm0> NGPRU3lUSU6JRWK=
NB12 NVTvcnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvPTWM2OD1zLkW2JI5O M4jVeHNCVkeHUh?=
HEL M{PqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TNZ2lEPTB;MT62NUBvVQ>? NXzK[lNPW0GQR1XS
GCIY M3\iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;XbW5UUUN3ME2xMlYzKG6P MX;TRW5ITVJ?
EHEB NWDZTFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\mVHZKSzVyPUGuOlchdk1? MkfBV2FPT0WU
TGBC1TKB M2D4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7WTWM2OD1zLkexJI5O M3LXdXNCVkeHUh?=
KURAMOCHI MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TiUGlEPTB;MT63NkBvVQ>? MV3TRW5ITVJ?
U-266 NH3pSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwN{[gcm0> NFHtd3lUSU6JRWK=
LC4-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwN{mgcm0> MWjTRW5ITVJ?
NCI-H2126 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHeweGRKSzVyPUGuPEBvVQ>? NXXufmxMW0GQR1XS
NCI-H1092 M136OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzaTWM2OD1zLkigcm0> MkX4V2FPT0WU
GB-1 M4G2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrjdGpKSzVyPUGuPFEhdk1? MWDTRW5ITVJ?
MV-4-11 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjEVYtKSzVyPUGuPFIhdk1? MWDTRW5ITVJ?
Becker MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\TTWM2OD1zLkizJI5O NXTyZlY4W0GQR1XS
MPP-89 M3TvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCe2pCUUN3ME2xMlg6KG6P NW\VTpJsW0GQR1XS
BE-13 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nuc2lEPTB;MT65N{BvVQ>? MX3TRW5ITVJ?
697 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwOUmgcm0> MWfTRW5ITVJ?
NKM-1 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\JZYVDUUN3ME2yJI5O M{LzN3NCVkeHUh?=
NB13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPienNKSzVyPUKgcm0> MorSV2FPT0WU
LS-123 NYXw[m4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO3TWM2OD1{LkCyJI5O MkDrV2FPT0WU
NB17 M{\2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfnXHhPUUN3ME2yMlA1KG6P NV3VcHBwW0GQR1XS
LAN-6 NIn3fYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\5TWM2OD1{LkC1JI5O M{eyW3NCVkeHUh?=
EW-24 NGLnfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwMEigcm0> Mkm2V2FPT0WU
NOS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zXJVKSzVyPUKuNVEhdk1? NYn4T2xNW0GQR1XS
BL-70 NFfoTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvL[FRKSzVyPUKuNVIhdk1? MUDTRW5ITVJ?
GT3TKB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXsOVViUUN3ME2yMlEzKG6P NFL0cWxUSU6JRWK=
HH NXTVRZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPEUVZmUUN3ME2yMlE{KG6P MVXTRW5ITVJ?
KE-37 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXiwNZg2UUN3ME2yMlE{KG6P MXLTRW5ITVJ?
MOLT-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\QRpI3UUN3ME2yMlE{KG6P NIq3O3pUSU6JRWK=
EKVX NGLaXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorDTWM2OD1{LkG0JI5O MkLYV2FPT0WU
KGN NUC3eJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TwZWlEPTB;Mj6xOUBvVQ>? MoDqV2FPT0WU
ES4 M{e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TrbWlEPTB;Mj6xOkBvVQ>? NHezNXdUSU6JRWK=
SJSA-1 NX3zN5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XzSmlEPTB;Mj6yNUBvVQ>? M1Lmb3NCVkeHUh?=
KMOE-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD1{LkKzJI5O MmX0V2FPT0WU
NB5 M2rxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r4bmlEPTB;Mj6yO{BvVQ>? NGXHZ3VUSU6JRWK=
BC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\QTWM2OD1{LkOxJI5O NGXyb5JUSU6JRWK=
NB10 NX[3NpppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHaTWM2OD1{LkOyJI5O NF\wfZpUSU6JRWK=
RPMI-8226 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjVO3pKSzVyPUKuN|Uhdk1? MoPlV2FPT0WU
SCC-3 NH3mZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe0TWM2OD1{LkO3JI5O NHHoSXdUSU6JRWK=
ARH-77 NX;seWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\jfnJKSzVyPUKuN|ghdk1? NV74PJJ{W0GQR1XS
NCI-H748 M2ficmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PDUGlEPTB;Mj6zPUBvVQ>? NIL1eXVUSU6JRWK=
KU812 NVKzcXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfwW|FWUUN3ME2yMlQzKG6P MVLTRW5ITVJ?
NCI-H64 NGnaOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfNWVN6UUN3ME2yMlQ1KG6P M3G0eXNCVkeHUh?=
NB69 NILGb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzLeZB6UUN3ME2yMlQ3KG6P NYDRSYh1W0GQR1XS
KNS-81-FD Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jIS2lEPTB;Mj60PEBvVQ>? NF62NnlUSU6JRWK=
LB1047-RCC MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\p[HlKSzVyPUKuOVchdk1? NIXLRWlUSU6JRWK=
EB-3 M1v6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPTnZ[UUN3ME2yMlY3KG6P MUfTRW5ITVJ?
Mo-T NWrlZmQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTjbWJDUUN3ME2yMlc1KG6P MXfTRW5ITVJ?
EW-16 M1ryPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW4NWg3UUN3ME2yMlc2KG6P Ml7rV2FPT0WU
CTV-1 NHj1fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\IPZlKSzVyPUKuPEBvVQ>? M3nabnNCVkeHUh?=
ETK-1 NYXmTFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJwOESgcm0> M3rzSHNCVkeHUh?=
C2BBe1 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TVPGlEPTB;Mj64PUBvVQ>? MkPsV2FPT0WU
MOLT-16 M160bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwOEmgcm0> MnzCV2FPT0WU
SW954 NH3RPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLGTWM2OD1{Lkmgcm0> NUnZRpJCW0GQR1XS
HT MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnTTVZKSzVyPUOuNFIhdk1? NF7scJVUSU6JRWK=
KARPAS-299 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XRSGlEPTB;Mz6wOkBvVQ>? NF\TVXhUSU6JRWK=
MONO-MAC-6 M{L0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7zPYFKSzVyPUOuNUBvVQ>? MVjTRW5ITVJ?
CGTH-W-1 NEi4co1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3flVWlEPTB;Mz6xJI5O MXPTRW5ITVJ?
SK-PN-DW M2HMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrKTWM2OD1|LkG0JI5O M1HyeHNCVkeHUh?=
CW-2 M4XmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHxWmNKSzVyPUOuNlEhdk1? NHP2RmhUSU6JRWK=
SK-N-DZ M37Pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHZeFRKSzVyPUOuNlYhdk1? NEfSTpFUSU6JRWK=
NEC8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ra[WlEPTB;Mz6zOUBvVQ>? MmniV2FPT0WU
LB996-RCC MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i1N2lEPTB;Mz60JI5O M33oV3NCVkeHUh?=
DB NIPhc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfNTWM2OD1|LkSxJI5O MWfTRW5ITVJ?
TE-15 NGHvV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme3TWM2OD1|LkSzJI5O MmrKV2FPT0WU
COR-L88 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwTWM2OD1|LkS3JI5O NH3J[ZZUSU6JRWK=
LAMA-84 NGPjdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwNEmgcm0> NWT2WVB4W0GQR1XS
MEG-01 NV7vOpRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwNEmgcm0> M3LKcHNCVkeHUh?=
LOXIMVI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nKV2lEPTB;Mz61JI5O MYLTRW5ITVJ?
RPMI-8402 M1PYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[0WJhwUUN3ME2zMlUhdk1? NWHQW|dLW0GQR1XS
KARPAS-45 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrMNXZ3UUN3ME2zMlU1KG6P NFHxOI9USU6JRWK=
HCC1187 NHThcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsd5BvUUN3ME2zMlU1KG6P NGm3OZpUSU6JRWK=
MZ1-PC MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKzTWM2OD1|LkW0JI5O MYXTRW5ITVJ?
no-11 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;UNlhYUUN3ME2zMlU2KG6P M2Xzc3NCVkeHUh?=
EVSA-T NFXtfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3EeoVKSzVyPUOuOkBvVQ>? M3j1cHNCVkeHUh?=
DJM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTNwNkOgcm0> MYPTRW5ITVJ?
COLO-684 NV7NN5ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O2RWlEPTB;Mz62OkBvVQ>? M1\2VnNCVkeHUh?=
NMC-G1 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjXSmhKSzVyPUOuOlghdk1? MnvIV2FPT0WU
LC-1F M2jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0WpV6UUN3ME2zMlc1KG6P MkO5V2FPT0WU
RL95-2 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwN{mgcm0> NWL4W4lLW0GQR1XS
COLO-320-HSR Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGySXhKSzVyPUOuPVIhdk1? MkDPV2FPT0WU
RCC10RGB Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfaTWM2OD1|LkmzJI5O MkKxV2FPT0WU
HD-MY-Z NVLkcYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWOxd|FiUUN3ME2zMlk{KG6P MVjTRW5ITVJ?
NCI-H2141 NUH6RW5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr6bGNYUUN3ME20MlA2KG6P MlTMV2FPT0WU
K-562 NI[5TGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LZbmlEPTB;ND6xNkBvVQ>? NXzpWotwW0GQR1XS
NCI-H1648 M1rCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TzRmlEPTB;ND6xN{BvVQ>? MmfkV2FPT0WU
OMC-1 NYrCVlZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRwMUigcm0> Mn61V2FPT0WU
LB647-SCLC MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ETWM2OD12LkKyJI5O MXfTRW5ITVJ?
TE-12 NEj3[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HXUWlEPTB;ND6yOUBvVQ>? Mn[2V2FPT0WU
NOMO-1 M17yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRwM{Ogcm0> M4\PWXNCVkeHUh?=
Raji MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PsUmlEPTB;ND60OkBvVQ>? MoLPV2FPT0WU
NALM-6 M2jwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRwNEmgcm0> NH7ITWJUSU6JRWK=
HL-60 M3S3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHhcm9KSzVyPUSuOlchdk1? MlPyV2FPT0WU
IST-SL1 NYnoXFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml23TWM2OD12Lk[4JI5O MW\TRW5ITVJ?
MHH-PREB-1 NYnPW5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj3b4pUUUN3ME20Mlg3KG6P MmnvV2FPT0WU
MHH-NB-11 M3H4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwOUGgcm0> Mm\hV2FPT0WU
JiyoyeP-2003 NIDJVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVibl2= Mom5V2FPT0WU
SBC-1 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;5dJZKSzVyPUWuNFEhdk1? MkSyV2FPT0WU
CHP-126 NYrJcZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPhTWM2OD13LkC2JI5O M3\MXnNCVkeHUh?=
LU-139 NXPpSWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVwMUOgcm0> MkXtV2FPT0WU
NCI-SNU-5 NED3b45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1bolrUUN3ME21MlE4KG6P M{Pad3NCVkeHUh?=
SW962 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jyPGlEPTB;NT6yNUBvVQ>? MkLSV2FPT0WU
EW-1 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwM{Ggcm0> NFPrVVFUSU6JRWK=
NCI-H1417 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXZcmNJUUN3ME21MlUyKG6P NUfNbmV7W0GQR1XS
LU-65 NVXpemVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNZnNyUUN3ME21Mlg1KG6P M2r2PHNCVkeHUh?=
D-502MG NWTVd212T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ixWGlEPTB;Nj6zO{BvVQ>? MmGwV2FPT0WU
BC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZwNkGgcm0> NGfjNYJUSU6JRWK=
GDM-1 NUWzcHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fkW2lEPTB;Nj63O{BvVQ>? M4XwSXNCVkeHUh?=
NCI-H2196 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vJWGlEPTB;Nj64JI5O M2TIW3NCVkeHUh?=
NB1 M2HJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;LVmlEPTB;Nj64PEBvVQ>? MYrTRW5ITVJ?
NCI-H345 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zhbmlEPTB;Nz6yJI5O M3TQUHNCVkeHUh?=
SU-DHL-1 NI\0TmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTdwMkSgcm0> MknsV2FPT0WU
JVM-2 NEDsUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdwMkigcm0> M1\tRXNCVkeHUh?=
LU-134-A MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTdwM{mgcm0> MlzHV2FPT0WU
NCI-H1694 NXnrZ3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjsTWM2OD15LkW4JI5O M1H4dXNCVkeHUh?=
NCI-SNU-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTRTWM2OD15Lk[1JI5O NW\nfVBSW0GQR1XS
L-363 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e2UmlEPTB;Nz63JI5O M164[XNCVkeHUh?=
KG-1 M{\wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTdwOUSgcm0> M1L0eHNCVkeHUh?=
MN-60 NXu5Nm46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP5TWM2OD16LkG0JI5O MlvuV2FPT0WU
NB6 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT1bmhKSzVyPUiuOFghdk1? M4T2V3NCVkeHUh?=
MLMA MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRThwOEWgcm0> MX\TRW5ITVJ?
ATN-1 NFzYToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j1fGlEPTB;OD64PUBvVQ>? MmO3V2FPT0WU
SK-NEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO0TWM2OD17LkCxJI5O NYOxTohZW0GQR1XS
DMS-114 NVvte3dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTMdZJyUUN3ME25MlYzKG6P MljQV2FPT0WU
CTB-1 NFvVWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hVmlEPTB;OT62O{BvVQ>? MkfzV2FPT0WU
NCI-H2081 NELDSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXyWZZEUUN3ME2xNE4xQSCwTR?= NULhbpIxW0GQR1XS
ES5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1VXFKSzVyPUGwMlM5KG6P NY\1R5hWW0GQR1XS
HCC1599 NI\PbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFzLkmxJI5O NX;KbIlQW0GQR1XS
NCI-H23 M4K0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF{LkGyJI5O M{C0XnNCVkeHUh?=
NCI-H1581 M4DOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6xTWM2OD1zMj6yPEBvVQ>? MlL5V2FPT0WU
JVM-3 M3LOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fGemlEPTB;MUKuPVkhdk1? NFnE[I5USU6JRWK=
NCI-SNU-1 NVPPe|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjSV5d3UUN3ME2xN{4yQSCwTR?= M{X3WXNCVkeHUh?=
NB7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnsTIdIUUN3ME2xOU46OiCwTR?= NIXTVFhUSU6JRWK=
JAR NUno[lU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvXTWM2OD1zNj6xN{BvVQ>? Mmf5V2FPT0WU
TGW NIPUTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfDTWM2OD1zNj60PEBvVQ>? Mmr0V2FPT0WU
U-87-MG M4Xzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjQc|BKSzVyPUG2Mlc3KG6P MlyyV2FPT0WU
NCI-H1436 NWD4UIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1zNz6wNUBvVQ>? NXHtVVZ{W0GQR1XS
GOTO NY\acXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF5LkC2JI5O MULTRW5ITVJ?
COLO-800 NHTzfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;YPGlEPTB;MUeuOlQhdk1? NE\GfW9USU6JRWK=
MFM-223 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3DWJZKSzVyPUG3MlkyKG6P MVvTRW5ITVJ?
EW-18 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF5Lkm2JI5O NHPtVpBUSU6JRWK=
NB14 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPFbpZoUUN3ME2xO{46QCCwTR?= M2PhRnNCVkeHUh?=
EB2 M3\IXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG4WVFKSzVyPUG4MlA5KG6P M4HyNnNCVkeHUh?=
EoL-1- NYDSboxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XROmlEPTB;MUiuN|Ehdk1? MX3TRW5ITVJ?
NCCIT M2nJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDjTWM2OD1zOD6zOkBvVQ>? NInSdpZUSU6JRWK=
DG-75 NIHBVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTqbINVUUN3ME2xPE43OSCwTR?= M4\mT3NCVkeHUh?=
HCC2218 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPuTHlYUUN3ME2xPU42KG6P NIDpTlhUSU6JRWK=
TE-6 M3rrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknSTWM2OD1{MD6wPEBvVQ>? M2TPcnNCVkeHUh?=
SF539 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDIfXRKSzVyPUKwMlY4KG6P M2DjenNCVkeHUh?=
NCI-H446 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJzLkG4JI5O M1S4enNCVkeHUh?=
IST-MES1 M4rGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ{Lke3JI5O NGfRO4ZUSU6JRWK=
NCI-H82 NHzVVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\0fY12UUN3ME2yN{4xOiCwTR?= MoHjV2FPT0WU
HCC2157 M1zVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH2XHpKSzVyPUKzMlE{KG6P MlTuV2FPT0WU
EW-12 M2rBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkG3JI5O NH\XWoZUSU6JRWK=
SIMA M3\6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;SRWdKSzVyPUKzMlM5KG6P NFrM[3JUSU6JRWK=
DOHH-2 M2XsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj2TWM2OD1{Mz60OUBvVQ>? MnTzV2FPT0WU
IM-9 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaTWM2OD1{Mz61OEBvVQ>? NGnKWGFUSU6JRWK=
EC-GI-10 M{jsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ThfGlEPTB;MkSuNlMhdk1? NV\qfolTW0GQR1XS
HDLM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XBd2lEPTB;MkSuOVQhdk1? M4rxbHNCVkeHUh?=
LS-1034 NX\lV2IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHvTWM2OD1{NT63OUBvVQ>? NUTjTIZJW0GQR1XS
REH NUTTW|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ4LkSxJI5O NH7zcFhUSU6JRWK=
LU-165 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHOdGlxUUN3ME2yOk44OiCwTR?= MWDTRW5ITVJ?
NH-12 NFXFOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nESmlEPTB;MkeuOlchdk1? MXrTRW5ITVJ?
WSU-NHL M3PxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGTWM2OD1{OD6zPUBvVQ>? MkfSV2FPT0WU
ECC4 M1;LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\4XWlEPTB;MkiuO|khdk1? NWS4WY9WW0GQR1XS
OCI-AML2 NHTHXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzHTWM2OD1{OT62PUBvVQ>? NFzt[HJUSU6JRWK=
EW-3 NFTVV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF24eHVKSzVyPUOwMlU6KG6P M4L3WXNCVkeHUh?=
NCI-H526 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LtOmlEPTB;M{KuOVQhdk1? NWXINZh{W0GQR1XS
NCI-H719 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMeGlEPTB;M{SuN|Ehdk1? MWTTRW5ITVJ?
KARPAS-422 M3LoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPJWZlDUUN3ME2zOU4xPCCwTR?= M365[XNCVkeHUh?=
SK-MEL-1 NX3yS2loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN3LkG3JI5O M1fZVHNCVkeHUh?=
ES3 NVvCXW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[xR2ZWUUN3ME2zOU4yQSCwTR?= MUPTRW5ITVJ?
UACC-812 NY\IUmgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN3LkS0JI5O M3rHWnNCVkeHUh?=
C8166 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfIO3ZKSzVyPUO1Mlchdk1? NE\DdlFUSU6JRWK=
MDA-MB-134-VI NEDwd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\yTmlEPTB;M{WuPFchdk1? M1v4cHNCVkeHUh?=
D-283MED NVvoOldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN5Lke5JI5O NGm1fmlUSU6JRWK=
SHP-77 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPaWYhKSzVyPUO4MlA{KG6P NVL4cGtoW0GQR1XS
NCI-H2227 NIrQbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTRyLkS5JI5O MkX3V2FPT0WU
SKM-1 NX3jN4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPETWM2OD12Mj62N{BvVQ>? MUjTRW5ITVJ?
L-428 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OzfGlEPTB;NEOuPFYhdk1? MUfTRW5ITVJ?
RPMI-6666 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR3Lki5JI5O M33BWnNCVkeHUh?=
NCI-H716 NVXHPWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zsVWlEPTB;NEiuPFEhdk1? M1e3NHNCVkeHUh?=
DMS-79 NW\yfVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMVYprUUN3ME21NE44OSCwTR?= MnzFV2FPT0WU
RS4-11 NFW3[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fVeWlEPTB;NUCuPFghdk1? M{jyR3NCVkeHUh?=
NCI-H720 NW\RXldLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7MTWM2OD13MT6xNUBvVQ>? MljnV2FPT0WU
MC-CAR MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJVGlEPTB;NUGuOVIhdk1? MUfTRW5ITVJ?
TALL-1 M{LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XwdmlEPTB;NUOuPVEhdk1? NEjyWWFUSU6JRWK=
NCI-N87 M{WyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwWoJKSzVyPUW0MlE5KG6P NX7PfmQ2W0GQR1XS
P30-OHK MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfpNXlFUUN3ME21OE43OSCwTR?= MlTWV2FPT0WU
LP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[yfY1KSzVyPU[xMlI5KG6P MlTTV2FPT0WU
YT NGfhRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HtUmlEPTB;NkGuPEBvVQ>? NWDiV2RnW0GQR1XS
MRK-nu-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZzLkiyJI5O M2TQSXNCVkeHUh?=
BT-474 M3vLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLyTWM2OD14NTDuUS=> NYLlVZFqW0GQR1XS
NCI-H322M NHi2N2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSzTWM2OD14Nj6xNUBvVQ>? MWrTRW5ITVJ?
NCI-H128 Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTd2Lke3JI5O NWn5V44xW0GQR1XS
KMS-12-PE MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLsTWM2OD15Nj6yOEBvVQ>? MYDTRW5ITVJ?
KP-N-YS NYm2c45rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTd4Lke0JI5O MWHTRW5ITVJ?
ALL-PO NHizN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTd5Lk[2JI5O NV7rVnlkW0GQR1XS
EW-13 NWLo[oE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITLRWpKSzVyPUe3Mlc3KG6P MVzTRW5ITVJ?
EW-11 NVfzVHdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\LSFFKSzVyPUe4MlUzKG6P M333eHNCVkeHUh?=
SK-N-FI M4q3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HYUGlEPTB;OECuNkBvVQ>? MnXsV2FPT0WU
CAL-148 NGXDfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;DOFlWUUN3ME24NU45PCCwTR?= MX7TRW5ITVJ?
RL NWq1cGpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDKTWM2OD16Nj6wPUBvVQ>? NITQWoRUSU6JRWK=
AM-38 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn25TWM2OD16OD6wPEBvVQ>? MVzTRW5ITVJ?
RH-1 NUS5[Yh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nmeWlEPTB;OUmuPFUhdk1? MYnTRW5ITVJ?
NCI-H1770 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e5c2lEPTB;MUCyMlQ6KG6P MYnTRW5ITVJ?
SIG-M5 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy0O|JKSzVyPUGwOU4xPiCwTR?= MojxV2FPT0WU
GR-ST M3XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHmeWxKSzVyPUGxN{4{PCCwTR?= MoPBV2FPT0WU
ST486 M4PG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKxU3U4UUN3ME2xNVQvODZibl2= MkXKV2FPT0WU
NCI-H1650 NXHFUJc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFzNT6yPUBvVQ>? M3v3TXNCVkeHUh?=
MHH-CALL-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD1TWM2OD1zMUWuO{BvVQ>? MUjTRW5ITVJ?
BV-173 M2fOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P1cWlEPTB;MUKyMlcyKG6P MlzhV2FPT0WU
MC116 M13RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7aSJVnUUN3ME2xOFgvQDVibl2= NYPyTIVVW0GQR1XS
NCI-H524 NHKy[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TVWWlEPTB;MUW5MlEhdk1? MXXTRW5ITVJ?
SCLC-21H M{HHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHKbINKSzVyPUG1PU41OSCwTR?= NWnGfIM5W0GQR1XS
NCI-H1304 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfwXHNkUUN3ME2xOlkvOjFibl2= NGC5WnpUSU6JRWK=
NCI-H510A NU\OZWd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF6NT6zO{BvVQ>? NFL6dFVUSU6JRWK=
NCI-H209 NIPuN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XacmlEPTB;MUm2MlUzKG6P MXvTRW5ITVJ?
KM-H2 NX7RS|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\DUWlEPTB;MUm3MlA2KG6P NUnzZ|ZzW0GQR1XS
NCI-H1395 NXfjSJE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJzMD6xN{BvVQ>? Mlj0V2FPT0WU
NCI-H1155 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ|MD6zNkBvVQ>? MmjnV2FPT0WU
COR-L279 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2izdWlEPTB;MkWyMlE4KG6P M1ywenNCVkeHUh?=
NCI-H1299 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PaTWlEPTB;Mk[xMlcyKG6P NHqxbldUSU6JRWK=
EW-22 NHjYNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRfGlEPTB;Mk[zMlc2KG6P NHjSS5RUSU6JRWK=
SK-MEL-2 NY\OdHI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX31VpBMUUN3ME2yPFEvQSCwTR?= NIrKb2ZUSU6JRWK=
KASUMI-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrPfplKSzVyPUK4N{4xPSCwTR?= M2DYXXNCVkeHUh?=
NCI-H187 M2H1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknmTWM2OD1{OEeuNFghdk1? MkHBV2FPT0WU
NCI-H2171 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D2OWlEPTB;Mki4MlkzKG6P MXjTRW5ITVJ?
LNCaP-Clone-FGC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ7NT6yOkBvVQ>? MWPTRW5ITVJ?
NCI-H1522 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\icJJkUUN3ME2zNFcvODVibl2= NYrBZ3NzW0GQR1XS
SCH M4rmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvWTWM2OD1|MkKuNlIhdk1? MorMV2FPT0WU
THP-1 M4Xu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrxTWM2OD1|MkKuOkBvVQ>? MmTLV2FPT0WU
SNU-C1 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvpVYFHUUN3ME2zOlIvODlibl2= MnnXV2FPT0WU
CA46 M4DkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HVmlEPTB;M{ezMlY{KG6P MUTTRW5ITVJ?
NCI-H1963 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN6Nj6xPUBvVQ>? MlW5V2FPT0WU
DEL Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:4TWM2OD1|OUGuNlchdk1? NF[wWVJUSU6JRWK=
TUR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjdmlEPTB;M{m2MlYyKG6P MVnTRW5ITVJ?
NCI-H226 NXLPeZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPlVXc4UUN3ME20NFMvOjNibl2= MWPTRW5ITVJ?
COLO-668 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3jTWM2OD12MEOuOVchdk1? M1LYRnNCVkeHUh?=
CPC-N M3T6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfPSmdKSzVyPUSwN{44PyCwTR?= NEfudXpUSU6JRWK=
NCI-H889 M3;EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETROpVKSzVyPUS2NU46OiCwTR?= MnrGV2FPT0WU
J-RT3-T3-5 NISxWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXVYlKSzVyPUWzNk42PyCwTR?= MmfNV2FPT0WU
MSTO-211H NITHcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rMcWlEPTB;NUe0MlI3KG6P NH7uUlFUSU6JRWK=
SCC-15 M3nGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4[lk1UUN3ME22OlcvPDdibl2= M1HGZXNCVkeHUh?=
SUP-T1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LkNmlEPTB;Nki2MlA1KG6P MXnTRW5ITVJ?
DMS-153 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd2Nj64N{BvVQ>? MlLhV2FPT0WU
MS-1 NGTxfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\rPHF4UUN3ME23OVkvPDJibl2= NX6xSoJkW0GQR1XS
TC-YIK MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTd6MT6wNUBvVQ>? NWPXZ2hFW0GQR1XS
RPMI-8866 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFyME[uNlgh|ryP MnzoV2FPT0WU
KY821 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71TWM2OD1zMEO2MlA1KM7:TR?= NUjDVZZVW0GQR1XS
P31-FUJ NHO2VpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17aR2lEPTB;MUGxNk44PSEQvF2= MoDFV2FPT0WU
COLO-824 M3;PWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF{NkGuO|gh|ryP NXrCS|dwW0GQR1XS
U-698-M NVzCS2d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4joPWlEPTB;MkK2Nk4yPSEQvF2= MlHHV2FPT0WU
TE-441-T M4rEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTpTWM2OD1{NUKxMlch|ryP MUXTRW5ITVJ?
IMR-5 M2\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXB[owxUUN3ME2zOFA6NjZ{IN88US=> MkTaV2FPT0WU
NCI-H1838 M{HSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5T2lEPTB;NEG4Ok4{OiEQvF2= NH35TZhUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID